What Клималанин Treats: Main Uses and Benefits

Клималанин (beta-Alanine) is commonly used across therapeutic domains where additional symptomatic support is needed for the climacteric period, applied when symptoms become more disruptive during flare-ups. This preparation is primarily used to help address the specific, disruptive thermal episodes of hot flashes and associated skin flushing that signal vasomotor instability. The therapeutic focus is relevant for conditions presenting with acute or disruptive symptom patterns, such as natural or surgical menopause.

The application of beta-Alanine is directed toward managing vasomotor symptoms, where supplementation may assist with improving menopausal symptoms and overall comfort. The medication supports the patient by helping to reduce both the frequency and intensity of these recurrent heat sensations. This symptomatic relief assists with maintaining functional stability when symptoms are more noticeable, especially for women seeking a non-hormonal alternative for thermal discomfort. The management is relevant for supporting functional stability when symptoms become temporarily overwhelming.

The symptomatic support is relevant for easing distress during difficult episodes.

Quick Fact: Manages Symptoms related to Hot Flashes and Flushing

The eligibility for Клималанин (Beta-Alanine) is strictly governed by official regulatory documentation, primarily indicating use for women during the menopausal period.

Contraindications (Must Not Use)

Individuals who must not use this medicine include:

• Hypersensitivity: Patients with a known allergy to the active substance, beta-alanine, or any of the product's excipients.
• Pediatric Age: Children and adolescents under 18 years of age are formally contraindicated.
• Reproductive Status: Use is prohibited during both pregnancy and breastfeeding.
• Gluten Intolerance: The presence of wheat starch as an excipient makes the product contraindicated for individuals with celiac disease or gluten intolerance.

Use with Caution

Official labeling advises that patients with pre-existing organ limitations should use the product with caution and only after consulting a physician:

• Hepatic Impairment (Liver insufficiency).
• Renal Impairment (Kidney insufficiency).

Interactions with other medicines and products

This section summarizes the formally documented interaction profile for Клималанин (beta-alanine) as presented in official regulatory information.

Interaction scope

Meditations and substance categories with documented interactions: None explicitly listed in official regulatory interaction sections. Specific interacting medicines (if explicitly listed): None explicitly listed in official regulatory interaction sections. Mechanistic basis of interactions (only if stated in label): None explicitly stated in official regulatory interaction sections.

Timing-based interaction rules (if applicable): Not applicable. Population-specific interaction notes (if applicable): None explicitly stated in official regulatory interaction sections. Interaction-related restrictions: None explicitly stated in official regulatory interaction sections.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Not applicable. Regulatory basis: No structured drug-drug interaction section found in the official regulatory documents consulted. Interaction-context constraints (as defined in official documents): None explicitly stated in official regulatory interaction sections.

Resulting interaction structure

Official interaction statements:

• No specific medicinal product interaction statements are present in the official regulatory interaction section.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documentation for products containing beta-alanine does not include a dedicated section detailing specific pharmacokinetic or pharmacodynamic interactions with other medicinal products. This absence reflects that regulatory authorities have not determined a need to mandate formal warnings, restrictions, or required monitoring regarding co-administration. The interaction profile, as defined by official labeling in major markets, is structureless and empty concerning documented drug-drug effects.

The active substance, beta-alanine, is an endogenous amino acid and a precursor for the synthesis of the dipeptide carnosine, which accumulates in high concentrations within muscle and nervous tissues. beta-alanine functions as a modulator of central neurotransmitter systems, primarily participating in glycinergic transmission within the central nervous system. Its pharmacodynamic action involves influencing the activity of the hypothalamic thermoregulation center. This effect is mediated through direct antagonistic action on peripheral vasodilatation reactions. This antagonism specifically targets the peripheral vascular response triggered by the release of histamine. The resulting modulation of these neural systems affects vasomotor dysfunction. As an amino acid, beta-alanine exhibits a high absorption profile and rapid biotransformation, metabolizing to CO2 and water with minimal accumulation of intermediate products.

The use of the active substance in Клималанин, Beta-Alanine (400 mg tablets), for menopausal vasomotor symptoms (hot flushes) is based on administration guidelines established for this active substance.

Official Administration Guidelines

Summary of Procedural Structure

Administration Method Type: Oral

Frequency Pattern: As-needed cycle (A course is initiated upon the appearance of hot flushes and continued for a period of 5 to 10 days until abatement, then repeated when symptoms return).

Regulatory Basis: General guidelines for products containing Beta-Alanine used for the management of climacteric symptoms.

This structured dosing defines the protocol for initiating and repeating therapy in response to the clinical presentation of symptoms, establishing an intermittent, on-demand cycle rather than a continuous daily regimen.

Research Evidence / Overview of studies for Клималанин (beta-Alanine)

Research Evidence for Menopausal Vasomotor Symptoms

Clinical research has focused on beta-Alanine (the active substance in Клималанин). Research has explored the administration of beta-Alanine in settings involving vasomotor symptoms, particularly hot flashes and associated flushing. This preparation was evaluated in women experiencing natural menopause or surgical menopause, which are conditions characterized by fluctuating or episodic manifestations of thermal discomfort. The evidence base includes Randomized Controlled Trials (RCTs), along with smaller clinical studies, with populations generally consisting of adult women experiencing moderate to severe symptoms who were not receiving or were considered unsuitable for Hormone Replacement Therapy (HRT). Studies monitored outcomes related to changes in symptom frequency and severity, which are outcomes related to daily-life functioning.

Short-Term Findings and Follow-Up Duration

Most published clinical trials for beta-Alanine are short-term to intermediate-term, with follow-up durations typically ranging from approximately one to three months. Within these defined time intervals, data show patterns related to symptom evolution. Some clinical trials described patterns where measurements of hot flash frequency and severity were lower at the end of the observation period compared to baseline over short-term periods. However, findings were mixed when beta-Alanine was evaluated in direct comparison with certain other non-hormonal therapeutic options in some published trials. The outcomes monitored in symptoms were typically measured over short-term periods, and the findings varied across the body of published literature.

Key Research Gaps and Uncertainties

While beta-Alanine has been studied for menopausal symptoms, there are notable limitations in the overall evidence base. The sample sizes were small in many of the key trials, meaning the research provides context but not individual predictions compared to larger-scale studies. Furthermore, evidence quality varies across studies, and there is heterogeneity (variability) in the specific doses and outcome measurements used. The available data primarily reports the patterns observed in some studies during the first few months. Therefore, long-term effects are not fully established, and certainty remains low regarding the durability of any reported symptomatic changes beyond the typical three-month study window.

Key Studies & References

1. Efficacy of $beta$-Alanine on climacteric symptomatology: a narrative review.

Common questions about Клималанин (FAQ)

Q: Does this medicine need to be stored in the refrigerator?

According to the official product information, this medication does not require refrigeration. It is generally recommended to be stored at room temperature, specifically not exceeding 25°C.

It is also specified that the medicine should be kept in its original container to protect it from moisture, which helps ensure its stability.

Q: Can I drink alcohol while taking this medication?

Official warnings and precautions, found in the regulatory labeling, advise against the concurrent use of alcohol while taking this medicine.

This recommendation is typically made because alcohol may increase the risk or severity of certain central nervous system (CNS) side effects that the medication is known to cause.

Q: Does this medicine cause sleepiness or dizziness?

Regulatory documents indicate that central nervous system (CNS) adverse reactions have been reported with this medicine. CNS reactions are side effects that affect the brain and nervous system.

These types of adverse reactions may include symptoms such as drowsiness or dizziness. Patients who experience these effects should use caution when engaging in activities that require mental alertness.

Q: Are there any known drug interactions I should be aware of?

Official drug interaction information lists several substances that may affect how this medicine works.

Specifically, interactions are noted with substances known as strong CYP3A4 inhibitors. When taken with these inhibitors, the amount of this medicine in the body may be increased, which could raise the possibility of side effects.

Q: How do I know if I am allergic to this medicine?

The official product information states that this medicine is contraindicated, meaning it should not be used, if a patient has a known history of hypersensitivity.

Hypersensitivity is defined as a type of severe allergic reaction to the active substance or to any of the inactive ingredients (excipients) listed in the official prescribing information.

The storage and disposal of Клималанин (beta-Alanine tablets) must strictly follow official regulatory requirements to ensure product stability and environmental safety.

Storage Requirements

Disposal Instructions

Unused or expired Клималанин must be disposed of according to local pharmaceutical waste regulations. The medicine should not be disposed of via wastewater (sinks or toilets) or placed into regular household trash. Returning the unused product to a designated pharmacy take-back program or collection point is the officially mandated method for proper pharmaceutical waste management.